Anti-PGR Antibody (R2Z69)

Catalog No.

RHC20005

Species reactivity

Human, Mouse, Rat

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:50-1:100

Target

Progesterone receptor, NR3C3, PGR, Nuclear receptor subfamily 3 group C member 3, PR

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P06401

Applications

IF, IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.5% BSA, 0.05% Sodium Azide and 50% Glycerol.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R2Z69

Enhancing diagnostic accuracy: Role of stomach-specific serum biomarkers in real-world risk-based sequential screening for malignant gastric lesions., PMID:40353072

Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay., PMID:39826800

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma., PMID:39626297

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies., PMID:39609425

Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population., PMID:39455684

[Intra-patient cancer heterogeneity and sacituzumab-govitecan efficacy.]., PMID:39446009

Immunohistochemical Analysis of GATA2 Expression in Endometrium and its Relationship with Hormone Receptor Expression in Benign and Premalignant Endometrial Disorders., PMID:39443360

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN., PMID:38977707

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide., PMID:38852017

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk., PMID:38649340

B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression., PMID:38503806

Endosomal protein expression of γ1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer., PMID:38265632

Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy., PMID:38136255

Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach., PMID:37905688

Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial., PMID:37770652

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma., PMID:37646702

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial., PMID:37532416

CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate., PMID:37432459

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival., PMID:37208678

Identification of new immune subtypes of renal injury associated with anti-neutrophil cytoplasmic antibody-associated vasculitis based on integrated bioinformatics analysis., PMID:37091784

[A Case of Locally Advanced Breast Cancer That Responded to Paclitaxel plus Bevacizumab and Underwent Radical Surgery]., PMID:36733163

Acute hypoxia induced dysregulation of clock-controlled ovary functions., PMID:36620217

[A Case of Breast Cancer Recurrence Responding to Trastuzumab Deruxtecan for Increased Cervical Lymph Node Metastasis during Anti-HER2 Therapy]., PMID:36412034

Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases., PMID:36408915

Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects., PMID:36251649

Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening., PMID:36249096

Immunocytochemical Reactivity Comparison between Formalin-Fixed and Liquid-Based Cytology-Fixed Specimens., PMID:36228592

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial., PMID:36209764

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA., PMID:36108425

The application of new gastric cancer screening score system for gastric cancer screening and risk assessment of gastric precancerous lesions in China., PMID:35868004

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience., PMID:35833190

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee., PMID:35768410

EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment., PMID:35682800

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer., PMID:35551360

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial., PMID:35550060

IL-27 promotes decidualization via the STAT3-ESR/PGR regulatory axis., PMID:35430461

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN., PMID:35418120

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment., PMID:35392438

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer., PMID:35240902

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study., PMID:35151415

High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series., PMID:35074178

Pre-Anthesis Cytokinin Applications Increase Table Grape Berry Firmness by Modulating Cell Wall Polysaccharides., PMID:34961114

HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer., PMID:34944801

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration., PMID:34760922

The Immunohistochemical Expression of MCM-3, -5, and -7 Proteins in the Uterine Fibroids., PMID:34449552

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma., PMID:34340951

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma., PMID:34290359

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert., PMID:34054104

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma., PMID:34050260

[The Treatment of Olaparib for BRCA Positive-Metastatic Breast Cancer Patient]., PMID:33790186

Document Download

Anti-PGR Antibody (R2Z69).pdf